Matrix metalloproteinase-9 (MMP-9) and matrix metalloproteinase-2 (MMP-2) play important roles in the progression of renal interstitial fibrosis (RIF). There is an increasing demand to construct a novel method for the simultaneous detection of MMP-9 and MMP-2 to monitor the progression of RIF. Herein, a strategy based on the nanoplatform composed of the polydopamine nanosphere and fluorescence-labeled aptamers is developed to simultaneously detect MMP-9 and MMP-2 with DNase-I-assisted recycling signal amplification. In the light of tracing the recovered fluorescence intensity at 520 and 610 nm upon adding MMP-9 and MMP-2, the increased fluorescence intensity is linear to the different concentrations of MMP-9 and MMP-2 with the detection limits of 9.6 and 25.6 pg/mL for MMP-9 and MMP-2, respectively. More intriguingly, the results of unilateral ureteral obstruction mice show that the concentration of MMP-9 in urine is increased with the extension of ligation time while the concentration of MMP-2 is reversed, indicating that the ratio of MMP-9 to MMP-2 could be considered as the potential urinary biomarker to evaluate the progress of RIF and the therapeutic effect of Huangkui capsule on RIF. Therefore, this study provides a paradigmatic strategy for the simultaneous detection of the dual markers of RIF, which is promising for the auxiliary clinical diagnosis and assessment of the prognosis of chronic kidney disease.

中文翻译：

---

将聚多巴胺纳米球/适体纳米平台与DNase-I辅助的循环扩增策略整合，以在肾间质纤维化过程中同时检测MMP-9和MMP-2。

基质金属蛋白酶9（MMP-9）和基质金属蛋白酶2（MMP-2）在肾间质纤维化（RIF）的进展中起重要作用。越来越需要构建一种同时检测MMP-9和MMP-2以监测RIF进展的新方法。本文中，开发了一种基于由聚多巴胺纳米球和荧光标记的适体组成的纳米平台的策略，以通过DNase-I辅助循环信号放大同时检测MMP-9和MMP-2。考虑到添加MMP-9和MMP-2后在520和610 nm处追回的荧光强度，增加的荧光强度与MMP-9和MMP-2的不同浓度呈线性关系，检出限为9.6和25.6 MMP-9和MMP-2分别为pg / mL。更有趣的是 单侧输尿管梗阻小鼠的实验结果表明，结扎时间的延长使尿中MMP-9的浓度升高，而MMP-2的浓度反而增加，表明可以考虑MMP-9与MMP-2的比例作为潜在的尿液生物标志物，可评估RIF的进展以及黄葵胶囊对RIF的治疗作用。因此，本研究为同时检测RIF的双重标志物提供了一种范例策略，有望为慢性肾脏病的辅助临床诊断和预后评估提供参考。提示MMP-9与MMP-2的比值可作为潜在的尿液生物标志物，以评估RIF的进展和黄葵胶囊对RIF的治疗作用。因此，本研究为同时检测RIF的双重标志物提供了一种范例策略，有望为辅助临床诊断和评估慢性肾脏病的预后提供希望。提示MMP-9与MMP-2的比值可作为潜在的尿液生物标志物，以评估RIF的进展和黄葵胶囊对RIF的治疗作用。因此，本研究为同时检测RIF的双重标志物提供了一种范例策略，有望为辅助临床诊断和评估慢性肾脏病的预后提供希望。